Jianglan Long

Title: Jianglan Long: Innovator in Tumor Treatment

Introduction

Jianglan Long is a prominent inventor based in Beijing, China. He has made significant contributions to the field of oncology through his innovative research and patent developments. His work focuses on improving treatment options for tumors that are unresponsive to immune checkpoint inhibitors.

Latest Patents

Jianglan Long holds a patent for the use of baicalin in the preparation of a drug aimed at treating tumors that are unresponsive to immune checkpoint inhibitors (ICIs) and undergoing hyperprogression. This patent addresses the challenges posed by excessive Foxp3Treg cells in various types of tumors, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), liver cancer, colorectal cancer (CRC), urothelial bladder cancer, and pancreatic cancer. The innovative approach combines baicalin with ICIs to effectively inhibit Foxp3Treg cells, thereby enhancing the anti-tumor sensitization effect.

Career Highlights

Jianglan Long is affiliated with Beijing Friendship Hospital, Capital Medical University, where he continues to advance his research in cancer treatment. His dedication to improving patient outcomes through innovative therapies has positioned him as a key figure in the medical community.

Collaborations

He collaborates with esteemed colleagues, including Dan Yan and Yu Zhang, to further his research and development efforts in oncology.

Conclusion

Jianglan Long's contributions to cancer treatment through his patent on baicalin demonstrate his commitment to addressing critical challenges in oncology. His work has the potential to significantly impact the treatment landscape for tumors resistant to current therapies.